EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access

Ten‐Year Outcome of Recanalization or Medical Therapy for Concomitant Chronic Total Occlusion After Myocardial Infarction

Anna van Veelen iD, Casper F Coerkamp iD, Yvemarie B O Somsen iD, Truls Råmunddal iD, Dan Ioanes, Peep Laanmets, René J van der Schaaf, Erlend Eriksen iD, Matthijs Bax iD, Maarten Jan Suttorp, Bradley H Strauss iD, Emanuele Barbato iD und 11 weitere

Journal of the American Heart Association · 2024

DOI: 10.1161/jaha.123.033556 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Anna van Veelen und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Heart Center, Amsterdam UMC, Location AMC Amsterdam Cardiovascular Sciences Amsterdam the Netherlands. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Coronary Occlusion, ST Elevation Myocardial Infarction. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The EXPLORE (Evaluating Xience and Left Ventricular Function in PCI on Occlusions After STEMI) trial was the first and only randomized trial investigating chronic total occlusion (CTO) percutaneous coronary intervention (PCI) early after primary PCI for ST‐segment–elevation myocardial infarction, compared with medical therapy for the CTO. We performed a 10‐year follow‐up of EXPLORE to investigate long‐term safety and clinical impact of CTO PCI after ST‐segment–elevation myocardial infarction, compared with no‐CTO PCI. Methods and Results In EXPLORE, 302 patients post‐ST‐segment–elevation myocardial infarction with concurrent CTO were randomized to CTO PCI within ≈1 week or no‐CTO PCI. We performed an extended clinical follow‐up for the primary end point of major adverse cardiac events, consisting of cardiovascular death, coronary artery bypass grafting, or myocardial infarction. Secondary end points included all‐cause death, angina, and dyspnea. Median follow‐up was 10 years (interquartile range, 8–11 years). The primary end point occurred in 25% of patients with CTO PCI and in 24% of patients with no‐CTO PCI (hazard ratio [HR], 1.11 [95% CI, 0.70–1.76]). Cardiovascular mortality was higher in the CTO PCI group (HR, 2.09 [95% CI, 1.10–2.50]), but all‐cause death was similar (HR, 1.53 [95% CI, 0.93–2.50]). Dyspnea relief was more frequent after CTO PCI (83% versus 65%, P =0.005), with no significant difference in angina.

Conclusions

This 10‐year follow‐up of patients post‐ST‐segment–elevation myocardial infarction randomized to CTO PCI or no‐CTO PCI demonstrated no clinical benefit of CTO PCI in major adverse cardiac events or overall mortality. However, CTO PCI was associated with a higher cardiovascular mortality compared with no‐CTO PCI. Our long‐term data support a careful weighing of effective symptom relief against an elevated cardiovascular mortality risk in CTO PCI decisions. Registration URL: https://www.trialregister.nl ; Unique identifier: NTR1108.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionCoronary OcclusionST Elevation Myocardial InfarctionHumansMaleFemaleMiddle AgedAgedTreatment OutcomeChronic DiseaseTime FactorsFollow-Up StudiesRisk Factors

Stichwörter der Autor:innen

chronic total occlusionclinical outcomepercutaneous coronary interventionrandomized controlled trial

Autor:innen und Institutionen

  • Department of Cardiology, Heart Center, Amsterdam UMC, Location AMC Amsterdam Cardiovascular Sciences Amsterdam the Netherlands.
  • Department of Cardiology, Heart Center, Amsterdam UMC, Location VUMC Amsterdam Cardiovascular Sciences Amsterdam the Netherlands.
  • Department of Cardiology Sahlgrenska University Hospital Gothenburg Sweden.
  • Department of Cardiology North-Estonia Medical Center Tallinn Estonia.
  • Department of Cardiology OLVG Hospital Amsterdam the Netherlands.
  • Department of Cardiology Haukeland University Hospital Bergen Norway.

ORCID-Profile: Anna van Veelen, Casper F Coerkamp, Yvemarie B O Somsen, Truls Råmunddal, Erlend Eriksen, Matthijs Bax, Bradley H Strauss, Emanuele Barbato, Koen M Marques, Martijn Meuwissen, Paul Knaapen, Jan G P Tijssen, Bimmer E P M Claessen, Loes P C Hoebers, José P S Henriques

Zitieren

APA

van Veelen, A., Coerkamp, C. F., Somsen, Y. B. O., Råmunddal, T., Ioanes, D., Laanmets, P., van der Schaaf, R. J., Eriksen, E., Bax, M., Suttorp, M. J., Strauss, B. H., Barbato, E., Marques, K. M., Meuwissen, M., Bertrand, O., van der Ent, M., Knaapen, P., Tijssen, J. G. P., Claessen, B. E. P. M., …, & EXPLORE investigators (2024). Ten‐Year Outcome of Recanalization or Medical Therapy for Concomitant Chronic Total Occlusion After Myocardial Infarction. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.033556

Vancouver

van Veelen A, Coerkamp CF, Somsen YBO, Råmunddal T, Ioanes D, Laanmets P, et al. Ten‐Year Outcome of Recanalization or Medical Therapy for Concomitant Chronic Total Occlusion After Myocardial Infarction. Journal of the American Heart Association. 2024. doi:10.1161/jaha.123.033556

BibTeX
@article{vanVeelen2024,
  author = {van Veelen, Anna and Coerkamp, Casper F and Somsen, Yvemarie B O and Råmunddal, Truls and Ioanes, Dan and Laanmets, Peep and van der Schaaf, René J and Eriksen, Erlend and Bax, Matthijs and Suttorp, Maarten Jan and Strauss, Bradley H and Barbato, Emanuele and Marques, Koen M and Meuwissen, Martijn and Bertrand, Olivier and van der Ent, Martin and Knaapen, Paul and Tijssen, Jan G P and Claessen, Bimmer E P M and Hoebers, Loes P C and Elias, Joëlle and Henriques, José P S and EXPLORE investigators, EXPLORE investigators},
  title = {Ten‐Year Outcome of Recanalization or Medical Therapy for Concomitant Chronic Total Occlusion After Myocardial Infarction},
  journal = {Journal of the American Heart Association},
  year = {2024},
  doi = {10.1161/jaha.123.033556}
}
Kostenlos starten →